Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2016

View Archived Issues

Vertex describes discovery of DNA-PK inhibitor

GlaxoSmithKline develops a second-generation HCV NS5A replication complex inhibitor

Zymeworks completes acquisition of Kairos Therapeutics

MN-166 receives FDA fast track designation for progressive multiple sclerosis

Bayer Schering Pharma discloses prostanoid FP receptor antagonists

Biolab Sanus Farmaceutica patents cyclic nucleotide inhibitors

HEC Pharm announces prostanoid DP2 receptor antagonists

Samumed divulges Wnt signaling inhibitors

RaQualia and Asahi Kasei Pharma enter new research collaboration agreement

Celyad and Institut Curie to collaborate on immuno-oncology program

Neuropore Therapies' NPT200-11 well tolerated in phase I study

Genisphere and University of Pennsylvania enter research agreement

Eiger BioPharmaceuticals completes merger with Celladon

Pfizer joins the Human Vaccines Project

Santen China and Chongqing Kerui enter a new strategic collaboration

OncoVent, a new company in China focusing on development of cancer immunotherapies

Bristol-Myers Squibb discloses novel HCV NS3 protease inhibitor

Aprecia Pharmaceuticals launches first FDA-approved 3D printed tablets

Lilly's ixekizumab approved in the U.S. for plaque psoriasis

OncoTherapy Science reports completion of phase I/II study of cancer vaccine OTSGC-A24

Alirocumab meets primary endpoint in ODYSSEY ESCAPE trial

BRD4 inhibitors demonstrate preclinical efficacy

bioLytical completes preclinical prototype assay to detect Zika, Dengue and Chikungunya antibodies

Janssen announces more collaborations through its DIA unit

Novel POLG2 variant may be associated with mitochondrial DNA depletion syndrome

AstraZeneca's ticagrelor stroke study misses primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...